Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Blood (2022) 140 (Supplement 1): 9670–9672.

https://doi.org/10.1182/blood-2022-162543

Published: 2022

Journal Articles

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Blood (2022) 140 (Supplement 1): 9668–9669.

https://doi.org/10.1182/blood-2022-159928

Published: 2022

Journal Articles

Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients

Benoit Tessoulin, Audrey Grain, Jocelyn Ollier, Thomas Gastinne, Viviane Dubruille, Béatrice Mahé, Nicolas Blin, Anne Lok, Sophie Vantyghem, Clara Sortais, Cyrille Touzeau, Philippe Moreau, Steven Le Gouill, Patrice Chevallier, Beatrice Clemenceau

Blood (2022) 140 (Supplement 1): 7411–7412.

https://doi.org/10.1182/blood-2022-163726

Published: 2022

Journal Articles

Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma

Baptiste Le Calvez, Yannick Le Bris, Thomas Gastinne, Viviane Dubruille, Béatrice Mahé, Nicolas Blin, Anne Lok, Sophie Vantyghem, Clara Sortais, Cyrille Touzeau, Steven Le Gouill, Philippe Moreau, Patrice Chevallier, Marion Eveillard, Marie C Bene, Benoit Tessoulin

Blood (2022) 140 (Supplement 1): 12766–12767.

https://doi.org/10.1182/blood-2022-170113

Published: 2022

Journal Articles

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Juliette Soret, Nabih Maslah, Cendrine Chaffaut, Françoise Boyer perrard, Fiorenza Barraco, Viviane Dubruille, Claude Capron, Amandine Tisserand, Valérie Rolland-Neyret, Zineb Ghrieb, Sylvie Chevret, Isabelle Plo, Marie-Hélène Schlageter, Veronique Meignin, Matthieu Resche-Rigon, Bruno Cassinat

Blood (2022) 140 (Supplement 1): 577–578.

https://doi.org/10.1182/blood-2022-156389

Published: 2022

Journal Articles

A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft

Patrice Chevallier, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Yannick Le Bris, Marion Eveillard, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Anne Lok, Cyrille Touzeau, Thomas Gastinne, Benoit Tessoulin, Maxime Jullien, Sophie Vantyghem, Philippe Moreau, Steven Le Gouill, Marie C Bene, Thierry Guillaume

Blood (2021) 138 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2021-149534

Published: 2021

Journal Articles

Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study

Alice Garnier, Maxime Jullien, Thierry Guillaume, Pierre Peterlin, Amandine Le Bourgeois, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Cyrille Touzeau, Thomas Gastinne, Anne Lok, Benoit Tessoulin, Sophie Vantyghem, Marie C Bene, Philippe Moreau, Steven Le Gouill, Patrice Chevallier

Blood (2021) 138 (Supplement 1): 4914.

https://doi.org/10.1182/blood-2021-146826

Published: 2021

Journal Articles

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients

Blood (2021) 138 (Supplement 1): 3908.

https://doi.org/10.1182/blood-2021-149178

Published: 2021

Journal Articles

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3911.

https://doi.org/10.1182/blood-2021-150439

Published: 2021

Journal Articles

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Blood (2021) 138 (Supplement 1): 2553.

https://doi.org/10.1182/blood-2021-146412

Published: 2021

Journal Articles

Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy

Blood (2021) 138 (Supplement 1): 3465.

https://doi.org/10.1182/blood-2021-149405

Published: 2021

Journal Articles

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine

Blood (2021) 138 (Supplement 1): 2895.

https://doi.org/10.1182/blood-2021-149139

Published: 2021

Journal Articles

Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy

Blood (2021) 138 (Supplement 1): 254.

https://doi.org/10.1182/blood-2021-149476

Published: 2021

Journal Articles

Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136743

Published: 2020

Journal Articles

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Srdan Verstovsek, MD PhD, Miklos Egyed, MD PhD, Ewa Lech-Marańda, MD PhD, Tomasz Sacha, MDPhD, Viviane Dubruille, MD, Stephen T. Oh, MD, Doroteya Todorieva-Todorova, MD, Francesco Passamonti, MD, Blanca Xicoy, MD, Björn Andréasson, MD PhD, Daniel El Fassi, MD, Claire Harrison, DM, FRCP, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Mary Frances Frances McMullin, MDFRCPath,FRCP, Christof Scheid, MD, MArianne Tang Severinsen, MD PhD, Mark M Kowalski, MD PhD, Gregg Smith, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-135872

Published: 2020

Journal Articles

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

Blood (2019) 134 (Supplement_1): 1985.

https://doi.org/10.1182/blood-2019-122013

Published: 2019

Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Blood (2019) 134 (Supplement_1): 2924.

https://doi.org/10.1182/blood-2019-128761

Published: 2019

Journal Articles

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Patrice Chevallier, MD, Pierre Peterlin, Alice Garnier, MD, Amandine Le Bourgeois, MD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Cyrille Touzeau, MD, Thomas Gastinne, MD, Anne Lok, MD, Benoit Tessoulin, MD PhD, Yannick Le Bris, PharmD, Marie C Bene, PharmSci, PhD, Steven Le Gouill, MD PhD, Philippe Moreau, MD, Thierry Guillaume, MD PhD

Blood (2019) 134 (Supplement_1): 4528.

https://doi.org/10.1182/blood-2019-125787

Published: 2019

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

NARROW

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients

Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft

Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine

Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy

Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only